Astex Pharmaceuticals

Cancer cell
#Astex Pharmaceuticals #Combination therapy #Mosaic Therapeutics #Oncology

Mosaic in-licenses clinical-stage oncology assets from Astex

Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical.  Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no,… Read More

#Business & Investment #Cancer Research #News

#Astex Pharmaceuticals #Bioorthogonal chemistry #Click chemistry #Cognitive impairment #Covid-19 #Drug discovery #Life sciences #Long Covid #Molecular Biology #Neuroscience #Public health

Podcast: Innovative approaches to improving drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More

#News

#Artificial intelligence (AI) #Astex Pharmaceuticals #Congruence Therapeutics #Polaris Quantum Biotech #Psivant Therapeutics #SandboxAQ

AI drug discovery research consortium adds six new members

OpenFold, a non-profit artificial intelligence (AI) research consortium focused on developing free and open-source software tools for biology and drug discovery, has added six new industry members. Joining the consortium are Astex Pharmaceuticals, Biogen, Congruence Therapeutics, Polaris Quantum Biotech, Psivant Therapeutics, and SandboxAQ. “This… Read More

#News

#Astex Pharmaceuticals #Cancer research #Collaboration #Merck #Oncology

Astex and MSD expand cancer drug discovery collaboration

Astex Pharmaceuticals and MSD (Merck & Co) have announced an exclusive worldwide research collaboration to identify small molecule candidates with activity towards a tumour suppressor protein for the treatment of cancer. Under the terms of the agreement, Astex will apply its fragment-based drug discovery platform to… Read More

#Business & Investment #News

Research laboratory
#Astex Pharmaceuticals #Cardiff University #Collaboration #Fragment-based drug discovery #Neurodegenerative disorders #Partnership

Multimillion pound collaboration targets neurodegeneration

Astex Pharmaceuticals and The Medicines Discovery Institute, Cardiff University (MDI) have agreed a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases.    The collaboration brings together the research expertise of Dr Emyr Lloyd-Evans and Dr Helen Waller-Evans in lysosomal biology,… Read More

#Business & Investment #News